Yaşlilikta Tedavi Kilavuzu indb

YAŞLILIKTA ORTAYA ÇIKAN ERKEK HİPOGONADİZMLİ HASTANIN YÖNETİMİ
Kaynaklar
1.  Trinick TR, Feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptoma-
tic testosterone deficiency in men. Aging Male 2011;14:10–15.
2.  Zengerling F, Schrader AJ, Cronauer MV, et al. The ‘‘AgingMales Symptoms’’ Scale (AMS): predictive value for 
lowered circulating androgens. Aging Male 2012;15:253–7.
3.  Brunton SA, Sadovsky R. Late onset male hypogonadism and testosterone replacement therapy in primary care. J 
FamPract 2010;59:1–8.
4.  Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with 
androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 
2010;95:2536–59.
5.  Kaplan SA, O’Neill E, Lowe RS, et al. Testosterone in aging men with benign prostati chyperplasia: data from the 
Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male 2013;16:48–51.
6.  Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova: Recommendations on the diagnosis, 
treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male, 2013; 16(4): 
143–15.
7.  Lee DM, Tajar A, Pye SR, et al. The EMAS StudyGroup. Association of hypogonadism with vitamin D status: 
theEuropean Male Ageing Study. Eur J Endocrinol 2012;166:77–85.
8.  Ekrem Kara, Özlem Çelik, Ateş Kadıoğlu, Pınar Kadıoğlu. Late-Onset Hypogonadism in Male Patients Over 60 
Years of Age with Metabolic Syndrome. Turkish Journal of Endocrinology & Metabolism 17.2 (2013).
9.  Schooling CM, AuYeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a 
systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57.
10.  Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations, anpitfalls in measurintestosterone: an EndocrineSocietyPo-
sition Statement. J Clin Endocrinol Metab 2007;92:405–13.
11.  G. Corona, MD, PhD, Endocrinologista,b, G. Rastrelli, MD, PhD, Endocrinologista, M. Maggi, MD, PhD, En-
docrinologist.Diagnosisandtreatment of late-onsethypogonadism: Systematic reviewand meta-analysis of TRT out-
comes. Best Practice&Research Clinical Endocrinology&Metabolism 2013;27: 557–579
12.  Huhtaniemi I &Forti G. Male late-onsethypogonadism: pathogenesis, diagnosis and treatment. Nature Reviews 
Urology 2011; 8: 335–344.
13.  Corona G, Rastrelli G, Vignozzi L et al. Emerging medication for the treatment of male hypogonadism. Expert 
Opinion on Emerging Drugs 2012; 17: 239–259.
14.  Matsui H, Takatsu Y, Tanaka A et al. Potent andefficient testosterone suppression by chronic administration of novel 
metastin analogues, TAK-448 and TAK-683, in malerats. European Jounal of Cancer Supplements 2012; 8: 66 
Abstract 251.
15.  Saad F, Aversa A, Isidori AM et al. Testosterone as potentialeffectivetherapy in treatment of obesity in men withtes-
tosteronedeficiency: a review. Current Diabetes Reviews 2012; 8: 131–143.
16.  McCullough AR, Khera M, Goldstein I et al. A multi-institutional observational study of testosterone level safter 
testosterone pellet (Testopel) insertion. Journal of Sexual Medicine 2012; 9: 594–601.
17.  Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the me-
tabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: thedouble-blindedplace-
bo-controlled Moscow study. Clin Endocrinol (Oxf ) 2010;73:602–12.

---

---

Bölüm